ITF Therapeutics
The Medical Science Liaison will develop and maintain scientific relationships with pediatric neurologists, neuromuscular specialists, and other key experts treating Duchenne muscular dystrophy across multiple states. The role involves scientific exchange, supporting clinical studies, delivering presentations, and contributing to medical affairs initiatives while traveling extensively.
Headquarters
Concord, Massachusetts, United States
Company Size
1-10 employees
Founded
2024
ITF Therapeutics LLC is the United States affiliate of Italfarmaco S.p.A., founded in 2024 and based in Concord, MA. The company focuses on bringing therapeutic options to people living with rare diseases, most notably commercializing DUVYZAT (givinostat), an FDA‑approved HDAC inhibitor for Duchenne muscular dystrophy (DMD), in the U.S. market. ITF combines a flexible, entrepreneurial approach with the resources and legacy of its parent organization to deliver treatments, support programs, and educational resources for patients, clinicians, and researchers.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for ITF Therapeutics.
86% above the average for this role
Medical Science Liaison (MSL) Director
Capricor Therapeutics
Medical Science Liaison (MSL)
Praxis Precision Medicines, Inc.
Senior Medical Science Liaison - DMD/Neuromuscular (West Coast)
REGENXBIO Inc
Medical Science Liaison
Pharvaris
Medical Science Liaison
Sarepta Therapeutics
Virtual Medical Science Liaison
lifelancer